MARKET

SYN

SYN

Synthetic
AMEX

Real-time Quotes | Nasdaq Last Sale

0.2199
+0.0016
+0.73%
After Hours: 0.2220 +0.0021 +0.96% 19:56 05/23 EDT
OPEN
0.2195
PREV CLOSE
0.2183
HIGH
0.2299
LOW
0.2171
VOLUME
479.40K
TURNOVER
0
52 WEEK HIGH
0.7200
52 WEEK LOW
0.1999
MARKET CAP
34.84M
P/E (TTM)
-1.0228
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 05/16 13:39
Recap: Synthetic Biologics Q1 Earnings
  Synthetic Biologics (AMEX:SYN) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Synthetic Biologics reported in-line EPS of $-0.03 versus an estimate of $-0.03.
Benzinga · 05/16 13:20
Synthetic Biologics GAAP EPS of -$0.03 in-line
Synthetic Biologics press release (NYSE:SYN): Q1 GAAP EPS of -$0.03 in-line. As of March 31, 2022, the company reported $56.7M in cash, which is expected to provide runway through the end
Seekingalpha · 05/16 12:05
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 05/16 09:18
Synthetic Biologics Q1 2022 Earnings Preview
Synthetic Biologics (SYN) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.03 Over the last 3 months, EPS estimates
Seekingalpha · 05/13 15:01
Notable earnings before Monday's open
BITF, CGEN, CLSN, CMRX, OTCQB:CVSI, GOED, KALA, LTRY, LUNA, MNMD, NOVN, OEG, PLX, PTE, SOHU, SSYS, SYN, SYRS, TCRT, WEJO, WIX, WRBY For Seeking Alpha's full earnings season calendar, click
Seekingalpha · 05/13 14:29
Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers
Benzinga · 05/10 16:24
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
More
No Data
Learn about the latest financial forecast of SYN. Analyze the recent business situations of Synthetic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SYN stock price target is 1.625 with a high estimate of 2.250 and a low estimate of 1.000.
High2.250
Average1.625
Low1.000
Current 0.2173
EPS
Actual
Estimate
-0.03-0.02-0.02-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 29
Institutional Holdings: 1.75M
% Owned: 1.10%
Shares Outstanding: 158.44M
TypeInstitutionsShares
Increased
3
253.42K
New
2
98.10K
Decreased
6
47.38K
Sold Out
5
523.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.86%
Pharmaceuticals & Medical Research
-0.17%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Kraws
Chief Executive Officer/Chief Financial Officer/Director
Steven Shallcross
Chief Operating Officer
Frank Tufaro
Independent Director
John Monahan
Independent Director
Jeffrey Wolf
No Data
No Data
About SYN
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Webull offers kinds of Synthetic Biologics Inc stock information, including AMEX:SYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYN stock methods without spending real money on the virtual paper trading platform.